Skip to main navigation Skip to search Skip to main content

Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma

  • Robert F. Cornell
  • , Veronika Bachanova
  • , Anita D'Souza
  • , Kwang Woo-Ahn
  • , Michael Martens
  • , Jiaxing Huang
  • , A. Samer Al-Homsi
  • , Saurabh Chhabra
  • , Edward Copelan
  • , Miguel Angel Diaz
  • , Cesar O. Freytes
  • , Robert Peter Gale
  • , Siddhartha Ganguly
  • , Mehdi Hamadani
  • , Gerhard Hildebrandt
  • , Rammurti T. Kamble
  • , Mohamed Kharfan-Dabaja
  • , Tamila Kindwall-Keller
  • , Hillard M. Lazarus
  • , David I. Marks
  • Taiga Nishihori, Richard F. Olsson, Ayman Saad, Saad Usmani, David H. Vesole, Jean Yared, Tomer Mark, Yago Nieto, Parameswaran Hari

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Abstract

Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL) is characterized by lymphoplasmacytic proliferation, lymph node and spleen enlargement, bone marrow involvement, and IgM production. Treatment varies based on the extent and biology of disease. In some patients, the use of allogeneic hematopoietic cell transplantation (alloHCT) may have curative potential. We evaluated long-term outcomes of 144 patients who received adult alloHCT for WM/LPL. Data were obtained from the Center for International Blood and Marrow Transplant Research database (2001 to 2013). Patients received myeloablative(n = 67) or reduced-intensity conditioning (RIC; n = 67). Median age at alloHCT was 53 years, and median time from diagnosis to transplantation was 41 months. Thirteen percent (n = 18) failed prior autologous HCT. About half (n = 82, 57%) had chemosensitive disease at the time of transplantation, whereas 22% had progressive disease. Rates of progression-free survival, overall survival, relapse, and nonrelapse mortality at 5 years were 46%, 52%, 24%, and 30%, respectively. Patients with chemosensitive disease and better pretransplant disease status experienced significantly superior overall survival. There were no significant differences in progression-free survival based on conditioning (myeloablative, 50%, versus RIC, 41%) or graft source. Conditioning intensity did not impact treatment-related mortality or relapse. The most common causes of death were primary disease and graft-versus-host disease (GVHD). AlloHCT yielded durable survival in select patients with WM/LPL. Strategies to reduce mortality from GVHD and post-transplant relapse are necessary to improve this approach.

Original languageEnglish
Pages (from-to)60-66
Number of pages7
JournalBiology of Blood and Marrow Transplantation
Volume23
Issue number1
DOIs
StatePublished - Jan 1 2017

Bibliographical note

Publisher Copyright:
© 2017 The American Society for Blood and Marrow Transplantation

Funding

Financial disclosure: The CIBMTR is supported by Public Health Service Grant/Cooperative Agreement U24-CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); a Grant/Cooperative Agreement 5U10HL069294 from NHLBI and NCI; a contract HHSH250201200016C with Health Resources and Services Administration (HRSA/DHHS); two Grants N00014-13-1-0039 and N00014-14-1-0028 from the Office of Naval Research; and grants from *Actinium Pharmaceuticals; Allos Therapeutics, Inc.; *Amgen, Inc.; Anonymous donation to the Medical College of Wisconsin; Ariad; Be the Match Foundation; *Blue Cross and Blue Shield Association; *Celgene Corporation; Chimerix, Inc.; Fred Hutchinson Cancer Research Center; Fresenius-Biotech North America, Inc.; *Gamida Cell Teva Joint Venture Ltd.; Genentech, Inc.; *Gentium SpA; Genzyme Corporation; GlaxoSmithKline; Health Research, Inc. Roswell Park Cancer Institute; HistoGenetics, Inc.; Incyte Corporation; Jeff Gordon Children's Foundation; Kiadis Pharma; The Leukemia & Lymphoma Society; Medac GmbH; The Medical College of Wisconsin; Merck & Co, Inc.; Millennium: The Takeda Oncology Co.; *Milliman USA, Inc.; *Miltenyi Biotec, Inc.; National Marrow Donor Program; Onyx Pharmaceuticals; Optum Healthcare Solutions, Inc.; Osiris Therapeutics, Inc.; Otsuka America Pharmaceutical, Inc.; Perkin Elmer, Inc.; *Remedy Informatics; *Sanofi US; Seattle Genetics; Sigma-Tau Pharmaceuticals; Soligenix, Inc.; St. Baldrick's Foundation; StemCyte, A Global Cord Blood Therapeutics Co.; Stemsoft Software, Inc.; Swedish Orphan Biovitrum; *Tarix Pharmaceuticals; *TerumoBCT; *Teva Neuroscience, Inc.; *THERAKOS, Inc.; University of Minnesota; University of Utah; and *Wellpoint, Inc. The views expressed in this article do not reflect the official policy or position of the National Institutes of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration (HRSA) or any other agency of the U.S. Government. This publication is funded in part by the Research and Education Program Fund, a component of the Advancing a Healthier Wisconsin endowment at the Medical College of Wisconsin and by KL2TR001438 from the Clinical and Translational Science Award program of the National Center for Advancing Translational Sciences.

FundersFunder number
Allos Therapeutics, Inc.
Teva Neuroscience, Inc.
U.S. Government
National Institutes of Health (NIH)
U.S. Department of Defense
Office of Naval Research Naval Academy
U.S. Department of Health and Human ServicesN00014-13-1-0039, N00014-14-1-0028
National Heart, Lung, and Blood Institute (NHLBI)
National Childhood Cancer Registry – National Cancer Institute
National Institute of Allergy and Infectious DiseasesHHSH250201200016C, 5U10HL069294
Health Resources and Services Administration
National Institute for Health Research Health Protection Research Unit
National Center for Advancing Translational Sciences (NCATS)KL2TR000113, KL2TR001438
University of Utah
U.S. Navy Air Systems Command
Actinium Pharmaceuticals Incorporated
Kiadis Pharma

    Keywords

    • Allogeneic stem cell transplant
    • Relapsed lymphoma

    ASJC Scopus subject areas

    • Hematology
    • Transplantation

    Fingerprint

    Dive into the research topics of 'Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma'. Together they form a unique fingerprint.

    Cite this